Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an update.
Hemogenyx Pharmaceuticals announced that its total issued share capital consists of 4,727,229 ordinary shares, with no shares held in treasury, resulting in the same number of voting rights. This information is crucial for shareholders to determine their notification requirements under the Financial Conduct Authority’s rules.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a clinical stage biopharmaceutical company based in London, with subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, leveraging several distinct product candidates and platform technologies.
Average Trading Volume: 38,039
Technical Sentiment Signal: Sell
Current Market Cap: £7.2M
For a thorough assessment of HEMO stock, go to TipRanks’ Stock Analysis page.